4120 logo

Orient EuroPharma Co., Ltd. Stock Price

TPEX:4120 Community·NT$4.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

4120 Share Price Performance

NT$0
-54.30 (-100.00%)
NT$0
-54.30 (-100.00%)
Price NT$0

4120 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet second-rate dividend payer.

2 Risks
0 Rewards

Orient EuroPharma Co., Ltd. Key Details

NT$4.6b

Revenue

NT$2.3b

Cost of Revenue

NT$2.3b

Gross Profit

NT$2.7b

Other Expenses

-NT$438.6m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-5.06
49.65%
-9.56%
44.6%
View Full Analysis

About 4120

Founded
1982
Employees
n/a
CEO
Meng-Lin Tsai
WebsiteView website
www.oepgroup.com

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient EuroPharma Co., Ltd. was incorporated in 1982 and is based in Taipei, Taiwan.

Recent 4120 News & Updates

Recent updates

No updates